J Physiol Wellcome Trust-funded researchers
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J Physiol Volume 563, Number 1, 119-137, February 15, 2005 DOI: 10.1113/jphysiol.2004.075788
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
563/1/119    most recent
jphysiol.2004.075788v1
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fischer, H.
Right arrow Articles by Huck, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fischer, H.
Right arrow Articles by Huck, S.

Selective deletion of the {alpha}5 subunit differentially affects somatic–dendritic versus axonally targeted nicotinic ACh receptors in mouse

Harald Fischer1, Avi Orr-Urtreger2, Lorna W Role3 and Sigismund Huck1

1 Division of Biochemistry and Molecular Biology, Centre for Brain Research, Medical University Vienna, Spitalgasse 4, A-1090 Vienna, Austria
2 The Genetic Institute, Tel Aviv Sourasky Medical Center and Sackler School of Medicine, Tel Aviv University, 6 Weizmann Street, Tel Aviv 64239, Israel
3 Center for Neurobiology and Behavior, College of Physicians and Surgeons, Columbia University, 722 West 168th Street, Research Annex Room 807, New York, NY 10032, USA


    Abstract
 Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 
We have compared the functional properties of nicotinic acetylcholine receptors (nAChRs) within both somatic and presynaptic domains of superior cervical ganglion (SCG) neurones from wild-type (WT) mice with those expressed by SCG neurones from mice with a targeted deletion of the gene for the {alpha}5-subunit. The functional profile of somatic nAChRs was assayed by direct macroscopic current recording and from measurements of nicotinic agonist-induced calcium transients with fura-2 imaging. The profile of nAChRs at presynaptic sites was assayed by measurement of nicotinic agonist-induced transmitter release (as preloaded [3H]noradrenaline) under conditions of action potential blockade. We have examined the responses to the nicotinic agonists acetylcholine, nicotine, cytisine, dimethylphenylpiperazinium iodide (DMPP) and epibatidine. Macroscopic current and calcium imaging assays revealed several differences in the functional profile of somatic nAChRs in WT SCG neurones compared with those from mice with the {alpha}5 subunit deleted. Somatic nAChRs in control animals were more potently activated by cytisine as compared to DMPP. In contrast, DMPP was consistently more potent than cytisine in mice lacking the {alpha}5 nAChR subunit. Differences in the somatic nAChR rank order of potency were most prominent after a least 1 day in vitro. The magnitude of somatic nAChR responses to nicotinic agonists was not substantially different in control mice compared with those of {alpha}5 subunit-deleted animals. Comparison of presynaptic nAChR-mediated responses in WT versus {alpha}5 subunit-deleted animals revealed a very different set of changes in the functional profile of prejunctional nAChRs compared with somatic nAChRs. In contrast to somatic nAChRs, the responses of prejunctional receptors were markedly enhanced in {alpha}5 knockout animals compared with control. Furthermore, all prejunctional receptor responses were most potently activated by DMPP in both control and in {alpha}5 subunit-deleted mice. Hence, the presence or absence of the {alpha}5 subunit did not affect the rank order of potency of agonists at preterminal sites but greatly affected the magnitude of presynaptic nAChR-mediated responses. The enhanced efficacy of nicotine at presynaptic receptors was corroborated in an acute atrium preparation from postnatal {alpha}5 subunit-deleted mice. These results confirm and significantly extend our previous observation that in the sympathetic nervous system, somatic and prejunctional receptors are different and rely on the presence of the {alpha}5 subunit in a distinct manner.

(Received 22 September 2004; accepted after revision 14 December 2004; first published online 20 December 2004)
Corresponding author S. Huck: Division of Biochemistry and Molecular Biology, Centre for Brain Research, Medical University Vienna, Spitalgasse 4, A-1090 Vienna, Austria. Email: sigismund.huck{at}meduniwien.ac.at


    Introduction
 Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 
Neuronal-type nicotinic acetylcholine receptors (nAChRs) play a pivotal role in trans-ganglionic signal transduction of the vegetative; nervous system (Wang et al. 2002b). The properties of these receptors have been studied extensively in the cholinergic (chick) ciliary ganglion (Williams et al. 1998; Conroy et al. 2000; Conroy et al. 2003), and in the chick (Yu & Role, 1998a,b; Devay et al. 1999) and rodent (Covernton et al. 1994; Silvilotti et al. 1997; Kristufek et al. 1999; Cuevas et al. 2000) sympathetic nervous system (for review see Skok, 2002).

The principal subunits that make up nAChRs in the vegetative nervous system are {alpha}3 and ß4 (McGehee & Role, 1995; Skok, 2002). In heterologous expression systems these two subunits are sufficient to form functional receptors (reviewed by McGehee & Role, 1995). However, RT-PCR analysis, measurements of ligand binding, reported effects of {alpha}-bungarotoxin, and studies of subunit-specific antibodies indicate the presence of {alpha}5, {alpha}7, ß2 and possibly {alpha}4 subunits in rodent superior cervical ganglion (SCG) (Skok, 2002). The inclusion of {alpha}5, {alpha}7 and ß2 nAChR subunits into ganglionic {alpha}3/ß4 pairs would be expected to change the functional profile of these receptors (Wang et al. 1996; Ramirez-Latorre et al. 1996; Groot-Kormelink et al. 1998; Gerzanich et al. 1998; Yu & Role, 1998a,b; Nelson & Lindstrom, 1999; Cuevas et al. 2000; Groot-Kormelink et al. 2001; Nelson et al. 2001; Nai et al. 2003).

Prior studies of the functional properties of nAChRs expressed by noradrenergic sympathetic or SCG neurones have primarily focused on receptors at somatic sites (Covernton et al. 1994; Mandelzys et al. 1995; Silvilotti et al. 1997; Yu & Role, 1998a,b). However, ganglionic neurones also have presynaptic (or prejunctional) nAChRs that are located on their axonal projections within the various target organs (Brain et al. 2001). Agonist-induced activation of these presynaptic nAChRs may generate antidromic volleys and cause the release of noradrenaline (Krauss et al. 1970).

We have previously shown (Kristufek et al. 1999) that prejunctional receptors are more sensitive to the nicotinic agonist 1,1-dimethyl-4-phenylpiperazinium iodide (DMPP), whereas somatic receptors in cultured rat SCG neurones are more potently activated by cytisine (Covernton et al. 1994; Kristufek et al. 1999). The distinct pharmacological profiles of somatic versus presynaptic nAChRs indicates fundamental differences in these receptor populations that may be due, at least in part, to differences in the subunit composition of the receptors (McGehee & Role, 1995; Nai et al. 2003). Attempts to dissect the subunit composition of these distinct receptors by comparing the properties of native receptors with receptors of defined composition expressed in heterologous systems have been less than successful in assigning a particular set of subunits that correspond to the functional profiles of rat SCG nAChRs (Covernton et al. 1994; Silvilotti et al. 1997; Lewis et al. 1997).

We have chosen a somewhat different tactic to the analysis of native subunit composition, examining the ‘pharmacological fingerprints’ (Covernton et al. 1994; Kristufek et al. 1999) of both somatic and prejunctional nAChRs in neurones from mice with functional deletions of a particular subunit (Champtiaux & Changeux, 2004). This report, as first part in a series of experiments, deals with studies on nicotinic receptors in the SCG from mice with a targeted deletion of the {alpha}5 subunit (Wang et al. 2002a,b, 2004; Salas et al. 2003). The general behaviour and gross anatomy of {alpha}5 knockout mice are similar to their wild-type littermates (reviewed by Wang et al. 2002b). However, {alpha}5 knockout mice are, for example less susceptible to nicotine-induced seizure (Kedmi et al. 2004), have more severe symptoms in experimental colitis (A. Orr-Urtreger, manuscript in preparation), and show an altered cardiac parasympathetic ganglionic transmission (Wang et al. 2002a). For a better understanding of the role of the {alpha}5 subunit in ganglionic transmission, the effects of {alpha}5 deletion now presented encourage one to take a second look for specific effects of nicotine in such mice.


    Methods
 Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 
Animals

Experiments were performed on cell cultures of dispersed SCG neurones or on acute atrial preparations taken from early postnatal mice with {alpha}5 subunit deficiency ({alpha}5 –/–) on C57BL/6J background and their wild-type ({alpha}5+/+) littermates (Salas et al. 2003).

Cell culture

Superior cervical ganglia were dissected from 4- to 6-day-old mouse pups humanely killed, as required by the Guidelines of the Animal Care Committee, by decapitation. The ganglia were dispersed to single cells, and plated as previously described (Boehm & Huck, 1995). Briefly, ganglia were freed from adhering connective tissue and blood vessels and incubated in a combination of collagenase IA (0.5 mg ml–1, Sigma) and dispase (1.0 mg ml–1, Roche Applied Science) for 20 min at 36.5°C. Subsequently, the ganglia were rinsed three times in Ca2+-free Tyrode solution and trypsinized (0.25% trypsin in Tyrode solution; Worthington) for 15 min at 36.5°C and dispersed by trituration in culture medium. Dispersed neurones were plated either onto 5-mm discs punched out of tissue culture dishes (Nunc) for experiments measuring transmitter release, or onto glass coverslips (Assistent) for patch-clamp recordings and fura-2 spectrofluorometry. Glass coverslips were treated by submersion in concentrated nitric acid for 2 days and thorough rinses thereafter with distilled water. Tissue culture discs and cleaned glass coverslips were coated with poly L-ornithine (100 mg (l H2O)–1; Sigma), followed by 250 µl laminin (Becton Dickinson; dissolved as 0.01 g l–1 in Neurobasal A medium, Gibco-Invitrogen). Approximately, 7500 cells were seeded into glass rings of 6 mm (release experiments) or 8 mm (patch clamp and calcium imaging) in order to confine them to the disc or the centre of the coverslip.

The culture medium consisted of Neurobasal A medium, supplemented with the B-27 additive (20 ml l–1; Gibco-Invitrogen), 25000 IU l–1 penicillin, 25 mg l–1 streptomycin (Gibco-Invitrogen), 0.5 mM L-glutamine (Sigma) and 20–50 µg l–1 nerve growth factor (NGF; R & D Systems).

Cultures meant for release experiments were maintained in the presence of 5% fetal bovine serum (Gibco-Invitrogen) and in 5% CO2, whereas the serum-free cultures used for calcium imaging and patch-clamp recordings were kept in 7% CO2.

Spectrofluorometry: fura-2 calcium imaging

Measurements of intracellular Ca2+ concentrations were performed at room temperature on an inverted Nikon Diaphot 300 microscope connected to a spectrofluorometrical calcium imaging system (VisiTech, Sunderland, UK). Cells on glass coverslips were ‘loaded’ with dye by incubation in culture medium including 5 µM acetoxymethyl ester form of fura-2 (fura-2 AM Molecular Probes). Preparations were rinsed twice with bathing solution prior to transfer to a recording chamber. The bathing (external) solution used for both calcium imaging and for patch-clamp analysis contained (mM): NaCl 120, KCl 3.0, CaCl2 2.0, MgCl2 2.0, glucose 20 and Hepes 10; adjusted to pH 7.3 with NaOH, and a final osmolarity of 280 mosmol l–1.

Changes in intracellular Ca2+ concentrations were determined by dual excitation at 340 and 380 nm, and by measuring emission at 510 nm. Measured F340/F380 ratios were transformed into Ca2+ concentration by the eqn (1) of Grynkiewicz (Grynkiewicz et al. 1985):


{tjp_701_m1}

(1)
where Rmin = Sf1/Sf2; Rmax = Sb1/Sb2; Keff = KD x Sf2/Sb2. [Ca2+] is the calculated calcium concentration; Rmin the calibration constant for F340/F380 ratio at zero free calcium; Rmax the calibration constant F340/F380 ratio for 39.8 µM free calcium; R the actually measured F340/F380 ratio; Sf1 the F340 determined by calibration with zero free calcium buffer; Sf2 the F380 determined by calibration with zero free calcium buffer; Sb1 the F340 determined by calibration with 39.8 µM free calcium buffer; Sb2 the F380 determined by calibration with 39.8 µM free calcium buffer; Keff the calibration constant; and KD the dissociation constant for fura-2 (224 nM at room temperature Grynkiewicz et al. 1985). The Keff, Rmin and Rmax calibration constants were determined for a given setting by measuring fura-2 fluorescence intensities in the absence or presence of 39.8 µM free calcium (Calcium Calibration Set, Molecular Probes).

Excitation light from a monochromatic fluorescent light source (QuantiCell FSM900, VisiTech) was directed to the sample via an appropriate filter set (Omega). Images were taken with a Nikon Fluor 40x/1.3 Ph4DL oil immersion objective and an intensified CCD camera (Stanford Photonics XR/Mega10 GEN III +). Registration of F340/F380 ratio images was at 1 Hz and controlled by the QuantiCell 2000 software (version 2.0e; VisiTech). We determined the Ca2+ concentrations in single cells off-line by selecting areas of interest from images recorded while applying our test substances. The effects of drugs were assessed by calculating the peak increase in intracellular calcium from baseline values. Nicotinic agonists were dissolved in recording buffer and applied in the presence of 0.5 µM tetrodotoxin (TTX, Latoxan) by a superfusion device (DAD-12, Adams & List) at a rate of one concentration per minute. Application times were adjusted to the occurrence of peak effects (12 s for low concentrations, 6 s for high concentrations of agonists).

Simultaneous calcium imaging and perforated-patch voltage-clamp recordings

Neurones loaded with fura-2 AM as described above were also assayed by electrophysiological recordings using perforated patch-clamp techniques (Rae et al. 1991). The recording pipettes had tip resistances of 1.5–3 M{Omega} when filled with 200 µg ml–1 amphotericin B (Sigma A-4888) in a standard internal solution containing (mM): K2SO4 75, KCl 55, MgCl2 8, Hepes 10, adjusted to pH 7.3 with (KOH). Cells were voltage clamped at –70 mV. For signal processing we used an Axopatch 200A (Axon Instruments) patch-clamp amplifier, a Digidata 1200 (Axon Instruments) A/D converter, and the pCLAMP 8 software (Axon Instruments).

[3H]Noradrenaline uptake and superfusion

The techniques for loading cultures with [3H]noradrenaline (NA) and subsequent superfusion for measurement of [3H]NA release were as previously described (Kristufek et al. 1999). Briefly, the cultures were incubated with 0.03 µM [3H]NA in culture medium containing 1 mM ascorbic acid for 60 min at 36.5°C. Culture discs were then transferred to low-volume chambers and superfused at 25°C with buffer containing (mM): NaCl 120, KCl 3, CaCl2 2, MgCl2 2, glucose 20, Hepes 10, fumaric acid 0.5, sodium pyruvate 5.0 and ascorbic acid 0.57; adjusted to pH 7.4 with NaOH. The rate of superfusion was 1 ml min–1, and superfusate was collected in 4-min samples before a 60-min washout period. Residual radioactivity within preparations after the release procedures was determined by extracting cultures at the end of an experiment with 1% sodium dodecyl sulphate (SDS). Radioactivity in extracts and collected fractions was determined by liquid scintillation counting.

Stimulation-induced radioactive outflow was achieved by adding nicotinic agonists to the superfusion medium for 15 s. Cultures were challenged with a first stimulus (S1) 12 min after the washout period (i.e. 72 min after initiation of superfusion) and to a maximum of three additional stimuli (S2, S3 and S4) at 20 min intervals. Concentration–response relationships for nicotinic agonists were established by a measuring a maximum of four stimuli with increasing concentrations of the agents in the absence or continuous presence of 0.25 µM TTX.

Mouse atria were taken from 6-day-old pups killed by decapitation and collected in ice-cold superfusion buffer containing (mM): NaCl 118, KCl 4.8, CaCl2 2.5, MgSO4 1.2, NaHCO3 25, KH2PO4 1.2, Na2-EDTA 0.03, glucose 11, ascorbic acid 0.57, fumaric acid 0.5 and sodium pyruvate 5.0; and bubbled with 95%O2–5%CO2. Loading of radioactivity was achieved by adding 0.03 µM [3H]NA and 1 mM ascorbic acid to superfusion buffer and incubating atria for 60 min at 36.5°C. One intact atrium was placed thereafter into each chamber and rinsed with superfusion buffer for 60 min before samples were collected at 4 min intervals. In order to block monocemine oxidase A (MAOA) activity and thus reduce the basal outflow of radioactivity, atria were exposed to 0.5 µM clorgyline for 20 min during the initial washout period (Kristufek et al. 2002). Stimulation-induced outflow of [3H]NA was achieved by either electrical field stimulation (120 monophasic pulses delivered at 3 Hz, 0.5 ms, 50 V cm–1, 40 mA), or by adding 100 µM nicotine (in the presence of 0.5 µM TTX) for 15 s to the superfusion buffer. Residual radioactivity was determined by extracting atria at the end of an experiment with 1% SDS and sonication.

Calculation of basal and stimulation-evoked [3H]NA outflow

Rates of [3H]NA outflow were obtained by dividing the amount of [3H]NA collected during a 4-min period by the total [3H]NA content of cultures at the beginning of the corresponding 4-min collection period (expressed as fractional rate). Basal outflow before the first stimulus (i.e. the basal fractional rate) was termed L1. Stimulation-evoked outflow was calculated as the difference between the total [3H]NA outflow during and after stimulation on the one hand, and the estimated basal outflow on the other hand, assuming that basal release follows a linear decline (Kristufek et al. 1999). The (stimulus-induced) difference was expressed as a percentage of the total radioactivity in the cultures at the beginning of the respective stimulation (S%, see Kristufek et al. 1999).

Calculation of concentration–response curves and potency ratios

All data are presented as arithmetic means ± S.E.M. The significance of differences was evaluated by means of the unpaired Student's t-test, unless indicated otherwise. Raw data from fura-2 imaging, patch-clamp recordings, and transmitter release experiments were converted into concentration–response curves using self-written script files for SigmaPlot 2000 (SPSS Inc.). Full concentration–response curves for agonists were fitted by unweighted non-linear regression to the logistic equation:


{tjp_701_m2}

(2)
where Ex is the response to a certain agonist concentration; x the arithmetic dose; Emax the maximal response; p a slope factor; and EC50 the dose that gives a half-maximal response. Computation utilized either SigmaPlot 2000 (SPSS Inc.) or the ALLFIT program (DeLean et al. 1978). The ALLFIT program calculates parameter estimates for EC50 values, the slope p (which is numerically identical to the Hill coefficient, see DeLean et al. 1978), and Emax, as well as appropriate standard errors and leaves the option to fit curves with or without shared parameters by non-linear regression. The program uses F statistics as the ‘extra sum of squares’ introduced when testing for independent versus shared parameters of two curves.

Low-concentration potency ratios were determined according to Covernton et al. (Covernton et al. 1994; Kristufek et al. 1999). Hence, dose–response curves (at the low-concentration end) were fitted simultaneously by non-linear regression with logistic equations that were constrained to be parallel (i.e. with a shared slope parameter, p). The maximum response was fixed to values deduced from full-range concentration–response curves of previous experiments. Adequacy of the fits was judged by eye (e.g. see Figs 2 and 8).



View larger version (29K):
[in this window]
[in a new window]
 
Figure 2.  Agonist-induced calcium transients and whole cell currents measured in {alpha}5 (+/+) SCG neurone
Examples are shown from one of the three {alpha}5 (+/+) neurones successfully assayed with both calcium imaging and whole cell current recording to assess the effects of agonist at the low end of the concentration–response curve. A, calcium transients, concurrently determined with whole-cell currents, in response to 12-s applications (indicated by bars) of nicotine, cytisine, DMPP or ACh (in the presence of 0.1 µM atropine). Concentrations were 3, 5 and 10 µM (nicotine, cytisine and DMPP, respectively), and 5 and 10 µM (ACh). Sharp deviations in current traces are due to the CCD camera shutter. The experiment was conducted on a 4 DIV preparation. B, dose–response relationship of peak calcium transients constructed from original recordings as shown in A. Data are mean peak transients measured in duplicate for each agonist. Curves based on eqn (2) were simultaneously fitted to data points by unweighted non-linear regression using the Allfit routine with the constraint of a shared slope and a fixed maximum as described in Methods. Filled inverted triangles and continuous line show the concentration–response curve for cytisine (Cyt); dashed lines and open symbols are effects of DMPP ({square}), nicotine (Nic, {circ}) and ACh ({diamond}). Potency ratios relative to cytisine (1.0) were 0.75 (DMPP), 0.51 (nicotine) and 0.39 (ACh). C, dose–response relationship of peak currents constructed from original recordings as shown in panel A. Data are mean peak transients measured in duplicate for each agonist. Curves based on eqn (2) were simultaneously fitted to data points by unweighted non-linear regression using the Allfit routine with the constraint of a shared slope and a fixed maximum as described in Methods. Filled inverted triangles and continuous line show the concentration–response curve for cytisine; dashed lines and open symbols are effects of DMPP ({square}), nicotine ({circ}) and ACh ({diamond}). Potency ratios relative to cytisine (1.0) were 0.81 (DMPP), 0.63 (nicotine) and 0.48 (ACh).

 


View larger version (23K):
[in this window]
[in a new window]
 
Figure 8.  Agonist-induced transmitter release from {alpha}5 (+/+) and {alpha}5 (–/–) SCG cultures at low agonist concentrations
A1, transmitter release was evaluated in preparations of SCG obtained from {alpha}5 (+/+) mice at 5 DIV that were preloaded with [3H]NA as described in Methods. Responses to DMPP ({square}) and cytisine ({blacktriangleup}) in the presence of 0.25 µM TTX are shown. Curves based on eqn (2) were simultaneously fitted to data points by unweighted non-linear regression using the Allfit routine with the constraint of a shared slope and a fixed maximum as described in Methods. Triangles and continuous line show the concentration–response curve for cytisine; dashed line and squares are effects of DMPP. In this assay, the potency of DMPP exceeded cytisine by a factor of 2.33 ± 0.03 (n = 3 individual cultures). This experiment, done in triplicate with 5 DIV cultures, yielded a mean potency ratio of 2.12 ± 0.16 (n = 9 cultures; see B1). A2, same experimental protocol as shown in A1, except that transmitter release was determined in 5 DIV cultures obtained from {alpha}5 (–/–) mice. The potency of DMPP exceeded cytisine by a factor of 2.39 ± 0.12 (n = 3 individual cultures). This experiment, done in triplicate with 5 DIV cultures, yielded a mean potency ratio of 2.00 ± 0.11 (n = 9 cultures; see B2). B1, time course of potency ratios determined in preparations of SCG obtained from {alpha}5 (+/+) mice after 2, 5 and 8 DIV. For each time point, the effects of DMPP and cytisine were determined in at least three release experiments similar to the one shown in A1. B2, time course of potency ratios determined in preparations of SCG obtained from {alpha}5 (–/–) mice after 2, 5 and 8 DIV. For each time point, the effects of DMPP and cytisine were determined in at least three release experiments similar to the one shown in A2.

 
Materials

Materials and reagents were obtained as noted and from the following sources: (–)-[ring-2,5,6 3H]noradrenaline (56.9 Ci mmol–1, NEN); acetylcholine chloride (ACh), 1,1,-dimethyl-4-phenylpiperazinium iodide (DMPP) cytisine, epibatidine and clorgyline hydrochloride from Sigma; and all other chemicals were from Merck (analytical grade).


    Results
 Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 
In the current series of experiments we established pharmacological fingerprints of somatic and prejunctional receptors in cultured SCG neurones by comparing the responses to five established nicotinic agonists: nicotine, cytisine, DMPP, ACh and epibatidine. Due to the relatively high calcium permeability of neuronal-type nAChRs, as compared with their muscle nAChR cousins (reviewed by McGehee & Role, 1995), the properties of receptors at somatic sites could also be assessed by spectrofluorometry using the Ca2+-sensitive dye, fura-2, in addition to patch-clamp recording. As in our previous study (Kristufek et al. 1999), functions of prejunctional receptors were monitored by measuring the outflow of preloaded [3H]NA as a result of calcium influx at sites of transmitter release. Generation of action potentials, and ensuing calcium entry through voltage-gated calcium channels, was prevented by adding TTX to the buffer solutions. We have shown previously that under these conditions, nicotinic agonists are unable to depolarize SCG varicosities sufficient for an activation of high voltage-activated calcium channels (Kristufek et al. 1999).

Somatic nAChRs: assessment of function by full concentration–response curves of nicotinic agonists and differences in rank order of potency between {alpha}5 (+/+) and {alpha}5 (–/–) mice

An assessment of potencies of nicotinic agonists by calcium imaging using fura-2, and deduced from full concentration–response curves in {alpha}5 (+/+) mouse SCG neurones after 4–5 days in vitro (DIV) (4/5 DIV) produced results very similar to patch-clamp observations previously made in the rat SCG (Covernton et al. 1994; Kristufek et al. 1999). Hence, out of the four classical agonists, cytisine was most potent to activate somatic receptors, followed by DMPP, nicotine and ACh (in the presence of 0.1 µM atropine; Fig. 1; Table 1). Potency ratios calculated from EC50 values (Table 1) relative to the standard cytisine (1.0) were 0.80 (DMPP), 0.64 (nicotine) and 0.26 (ACh). These values are strikingly close to those obtained in rat (DMPP, 0.62; nicotine, 0.60; Ach, 0.34; all relative to cytisine Kristufek et al. 1999). In all assays presented in our present study, the potency of epibatidine exceeded the most potent concurrent nicotinic agonist by at least three orders of magnitude (Figs 1 and 7, and Table 1 and 2).



View larger version (24K):
[in this window]
[in a new window]
 
Figure 1.  Enhancement of somatic calcium signalling response to nicotinic agonists: comparison between {alpha}5 (+/+) and {alpha}5 (–/–) mice
A–E, calcium transients in the soma region were recorded by fura-2 calcium imaging in response to DMPP (A), cytisine (B), nicotine (C), ACh (in the presence of 0.1 µM atropine, D) and epibatidine (E). Recordings were done in the presence of 0.5 µM TTX. Full concentration–response curves for each of the agonists were determined in at least 20 neuronal somata of two to three different preparations of control or of {alpha}5 (–/–) neurones (4–5 DIV). Values of individual cells were normalized with respect to the concentrations yielding maximum response (DMPP and nicotine, 67 µM; cytisine and Ach, 200 µM; epibatidine, 67 nM), and then fitted for determination of EC50 values using eqn (2). Results from {alpha}5 (+/+) animals are indicated by filled symbols and continuous lines, those from {alpha}5 (–/–) by open symbols and dashed lines. Fitted parameters are summarized in Table 1. There were only minor differences in EC50 values between genotypes with the exception of cytisine. Cytisine was more potent in {alpha}5 (+/+) as compared to {alpha}5 (–/–) mice (EC50: {alpha}5 (+/+), 9.27 ± 0.18 µM; {alpha}5 (–/–), 14.95 ± 0.47 µM; P < 0.01). F, maximum calcium signal for each agonist at somatic nAChRs obtained by fitting the dose–response to eqn (2) without prior normalization. Open columns are results from {alpha}5 (+/+) mice, hatched columns are the surplus of responses as seen in {alpha}5 (–/–) animals. All agonists show a tendency towards higher efficacy in the {alpha}5 (–/–) responses, although the difference is only significant for DMPP (344 ± 11 nMversus 443 ± 17 nM; n = 20 and 24 for {alpha}5 (+/+) and {alpha}5 (–/–) mice, respectively; P < 0.01), epibatidine (499 ± 24 nMversus 599 ± 28 nM; n = 20 for both {alpha}5 (+/+) and {alpha}5 (–/–); P < 0.05) and cytisine (370 ± 17 nMversus 438 ± 23 nM; n = 26 and 30 for {alpha}5 (+/+) and {alpha}5 (–/–); P < 0.05). Maximal effects of ACh in {alpha}5 (+/+) animals (530 ± 29 nM; n = 20) were significantly larger than effects of DMPP (P < 0.01), cytisine (P < 0.01), and nicotine (P < 0.05). In {alpha}5 (–/–) animals, the maximal effects of ACh (551 ± 27 nM; n = 22) significantly exceeded those of DMPP and cytisine (P < 0.01).

 

View this table:
[in this window]
[in a new window]
 
Table 1.  Enhancement of somatic calcium by saturating concentrations of nicotinic agonists: comparison between {alpha}5 (+/+) and {alpha}5 (–/–) mice
 


View larger version (29K):
[in this window]
[in a new window]
 
Figure 7.  Transmitter release in response to activation of prejunctional nicotinic acetylcholine receptors: comparison between {alpha}5 (+/+) and {alpha}5 (–/–) mice
A–E, transmitter release overflow was evaluated in preparations at 4–6 DIV that were preloaded with [3H]NA as described in Methods. Responses in the presence of 0.25 µM TTX to DMPP (A), cytisine (B), nicotine (C), ACh (in the presence of 0.1 µM atropine, D) and epibatidine (E) are shown. Data points show the number of counts min–1 of [3H]NA normalized with respect to the maximum effect for each agonist in a particular experiment (DMPP, 66–100 µM; nicotine, 60–120 µM; cytisine, 75–166 µM; Ach, 150–600 µM; epibatidine, 66–100 nM) and are the averaged values from three individual cultures. Note that beyond these maximum concentrations, the effect of agonists decline again. Curves show the results of fitting eqn (2) to data points with the constraint that the maximum response was set to 1.0. Data points of supramaximal agonist concentrations were excluded from the fits. Fit parameters for EC50 values and the slope factors are shown in Table 2. The symbols used to depict results for {alpha}5 (+/+) and {alpha}5 (–/–) animals, respectively, are indicated in each panel. F, the maximal NA release was calculated by averaging all maximal effects an agonist had in individual cultures of either the {alpha}5 (+/+) or the {alpha}5 (–/–) genotype. Data are means ± S.E.M.; n = 9 (DMPP at {alpha}5 (+/+)) to 27 (cytisine and ACh at {alpha}5 (–/–)) individual cultures. Open columns are results from {alpha}5 (+/+) mice, hatched columns are the surplus of responses as seen in {alpha}5 (–/–) animals. Note the striking difference of the maximal release which is independent of the type of agonist (P < 0.01). The overall maximal NA outflow (pooled data from all five agonists) was 2.67-fold larger in {alpha}5 (–/–) than in {alpha}5 (+/+) animals ({alpha}5 (+/+), 6.82 ± 0.49%, n = 65; {alpha}5 (–/–), 18.23 ± 0.42%, n = 112; P < 0.01). Maximal effects of ACh in {alpha}5 (+/+) animals (7.63 ± 1.28 %; n = 15 individual cultures) did not significantly differ from the maximal effects of the other agonists (P > 0.05). Maximal effects of ACh in {alpha}5 (–/–) animals (18.39 ± 1.01 %; n = 27 individual cultures) did not significantly differ from the maximal effects of the other agonists (P > 0.05).

 

View this table:
[in this window]
[in a new window]
 
Table 2.  Transmitter release in response to activation of prejunctional nicotinic acetylcholine receptors: comparison between {alpha}5 (+/+) and {alpha}5 (–/–) mice
 
With one notable exception, cytisine, the EC50 values for the activation of somatic receptors were not substantially different in {alpha}5 (+/+) and {alpha}5 (–/–) mice (Fig. 1; Table 1). Cytisine was about 1.6 times less potent in the {alpha}5 (–/–) mice compared with {alpha}5 (+/+) controls (Fig. 1; Tables 1, P < 0.01). This shift of potency was sufficiently large to change the rank order of agonist potency in the {alpha}5 (–/–) animals to DMPP (1.50), followed by cytisine (1.0), nicotine (1.00) and ACh (0.42).

In addition to the significant effects on rank order of agonist potency, there was a trend towards increased efficacy of a subset of the nicotinic agonists, as assessed from the magnitude of the somatic responses in {alpha}5 (–/–) versus {alpha}5 (+/+)-derived neurones (Fig. 1F). Thus, the maximum increases in calcium measured in {alpha}5 (–/–) animals were significantly larger in response to cytisine (P < 0.05), DMPP (P < 0.01) and epibatidine (P < 0.05) but did not differ significantly for nicotine and ACh (Fig. 1F). The trend towards a higher maximum responses was also apparent in analyses of data pooled for all agonists (Fig. 1F, overall). Hence, in {alpha}5 (–/–) mice, the maximum increase of calcium in response to the agonists exceeded the effects in {alpha}5 (+/+) mice by a factor of 1.14 (P < 0.01, n = 113 and 123 for {alpha}5 (+/+) and {alpha}5 (–/–) mice, respectively).

Somatic nAChRs: assessment of function by low concentration potency ratios confirms results of full concentration–response curves

Estimates of EC50 values when deduced from full concentration–response curves may be misleading (Covernton et al. 1994; Kristufek et al. 1999). Therefore, we used an additional approach to compare the potencies of our four standard agonists at concentrations not exceeding EC50 values (‘low-concentration potency ratios’, see Covernton et al. 1994). This approach minimizes the contribution of receptor desensitization seen at high concentration of agonists and eliminates ‘between neurone’ variance as comparative measurements of potency ratios can be done on the same cells (Figs 2 and 3). Potency ratios determined from individual neurones could then be pooled for calculation of the statistics (Fig. 4).



View larger version (29K):
[in this window]
[in a new window]
 
Figure 3.  Agonist-induced calcium transients and whole cell currents measured in {alpha}5 (–/–) SCG neurone
Examples are shown from one of the three {alpha}5 (–/–) neurones successfully assayed with both calcium imaging and whole cell current recording to assess the effects of agonist at the low end of the concentration–response curve. A, calcium transients, concurrently determined with whole-cell currents, in response to 12-s applications (indicated by bars) of nicotine, cytisine, DMPP or ACh (in the presence of 0.1 µM atropine). Concentrations were 3, 5 and 10 µM (nicotine, cytisine and DMPP, respectively), and 5 and 10 µM (ACh). Sharp deviations in current traces are due to the CCD camera shutter. The experiment was conducted on a 4 DIV preparation. B, dose–response relationship of peak calcium transients constructed from original recordings as shown in A. Data are mean peak transients measured in duplicate for each agonist. Curves based on eqn (2) were simultaneously fitted to data points by unweighted non-linear regression using the Allfit routine with the constraint of a shared slope and a fixed maximum as described in Methods. Filled inverted triangles and continuous line show the concentration–response curve for cytisine (Cyt); dashed lines and open symbols are effects of DMPP ({square}), nicotine (Nic, {circ}) and ACh ({diamond}). Potency ratios relative to cytisine (1.0) were 1.21 (DMPP), 0.74 (nicotine) and 0.37 (ACh). C, dose–response relationship of peak currents constructed from original recordings as shown in A. Data are mean peak transients measured in duplicate for each agonist. Curves based on eqn (2) were simultaneously fitted to data points by unweighted non-linear regression using the Allfit routine with the constraint of a shared slope and a fixed maximum as described in Methods. Filled inverted triangles and continuous line show the concentration–response curve for cytisine; dashed lines and open symbols are effects of DMPP ({square}), nicotine ({circ}) and ACh ({diamond}). Potency ratios relative to cytisine (1.0) were 1.49 (DMPP), 0.88 (nicotine) and 0.49 (ACh).

 


View larger version (14K):
[in this window]
[in a new window]
 
Figure 4.  Time dependence of low-dose potency ratios of nicotinic agonists in {alpha}5 (+/+) and {alpha}5 (–/–) mice: somatic receptors
A, low-dose potency ratios were determined in individual cells from {alpha}5 (+/+) mice at the indicated age of cultures and as shown in Fig. 2 for a cell after 4 DIV. Data points are mean potency ratios ± S.E.M. (relative to the standard, cytisine) of 6 (1 DIV), 12 (2 DIV), 21 (4 DIV), 7 (6 DIV), 2 (9 DIV) and 6 (12 DIV) neurones. Filled inverted triangles and continuous line show the potency ratio for cytisine, set to unity; dashed lines and open symbols are the ratios of DMPP ({square}), nicotine ({circ}) and ACh (in the presence of 0.1 µM atropine, {diamond}). Note the significant change of potency ratios, particularly for DMPP, between 1 and 6 DIV (P < 0.01). At 1 DIV, the DMPP to cytisine ratio was 0.30 ± 0.02 (n = 6; significantly different from 1: P < 0.01), from where it increased up to 0.95 ± 0.01 (n = 7) after 6 DIV. B, results obtained from {alpha}5 (–/–) mice by the protocol described in A; symbols identical to A. Data points are mean potency ratios ± S.E.M. (relative to the standard, cytisine) of 6 (1 DIV), 16 (4 DIV), 8 (6 DIV), 14 (7 DIV) and 8 (12 DIV) neurones. Note that regardless of the age of cultures, DMPP was consistently more potent than cytisine. At 1 DIV, the DMPP to cytisine ratio was 1.39 ± 0.01 (n = 6; significantly different from 1: P < 0.01). At 7 DIV, the DMPP to cytisine ratio was 1.37 ± 0.02 (n = 14).

 
Potency ratios determined at lower agonist doses confirmed our findings on the differences in rank order potency and potency ratios of neurones from {alpha}5 (+/+) versus {alpha}5 (–/–) mice, as deduced from the EC50 values. Hence, in SCG neurones of {alpha}5 (+/+) mice, cytisine was the most potent agonist, followed by DMPP and nicotine, and then ACh (1, 0.67 ± 0.02, 0.68 ± 0.03 and 0.51 ± 0.02, respectively; means ± S.E.M., n = 21 from four different preparations; see Fig. 4A, data points at 4 DIV). In contrast, examination of SCG neurones from {alpha}5 (–/–) mice revealed the distinct rank order potency of DMPP > cytisine > nicotine > > ACh. Thus direct assessment of low-concentration potency ratios (cytisine, 1; DMPP, 1.34 ± 0.02; nicotine, 0.90 ± 0.01; Ach, 0.30 ± 0.01; means ± S.E.M., n = 16 out of three different preparations; see Fig. 4B, data points at 4 DIV) confirms the results obtained from full dose–response curves.

Simultaneous fura-2 calcium imaging and patch-clamp recordings in the same cell further confirmed the differences of somatic nAChRs agonist potency ratios between {alpha}5 (+/+) and {alpha}5 (–/–) mice. Both techniques yielded identical potency ratios in within genotype comparisons of either {alpha}5 (+/+) or {alpha}5 (–/–) mice (compare Figs 2 and 3). It is notable that the time course of calcium transients was much slower than the evoked currents recorded in response to application of agonists. In addition we noted a trend towards higher magnitude changes in DMPP-evoked Ca2+ signalling in neurones from {alpha}5 subunit-deleted mice (compare Figs 2 and 3).

Potency ratios are affected by the age of cultures in {alpha}5 (+/+) mice, but not in {alpha}5 (–/–) mice

All observations presented so far were made on mouse SCG neurones maintained in culture for 4–5 days. However, the subunit composition of nAChRs changes with the age of cultures (De Koninck & Cooper, 1995). We therefore wanted to know whether these changes were paralleled by an adjustment of potency ratios. It is striking that cytisine has an exceedingly high potency compared to the other agonists when tested after 1 DIV in SCG neurones from {alpha}5 (+/+) mice (potency ratio of DMPP compared to cytisine, 0.30 ± 0.02, means ± S.E.M.; n = 6 of two preparations, Fig. 4A). By 4 DIV, the ratio declined to 0.67 ± 0.02 (n = 21 of four preparations, see above), and after 6 DIV, DMPP and cytisine were almost equipotent in neurones from {alpha}5 (+/+) mice (cytisine, 1; DMPP, 0.95 ± 0.01, n = 7 of two preparations; difference to 1 DIV significant at P < 0.01). The changes in the potency of nicotine and ACh initially followed the time course of DMPP, but then declined relative to DMPP after 9 and 12 DIV (Fig. 4A).

In contrast to the developmental changes in somatic responses in {alpha}5 (+/+) animals, somatic nAChRs of {alpha}5 (–/–) mice remained about constant throughout the incubation period. DMPP was more potent than cytisine at all points examined (potency ratio after 1 DIV, 1.39 ± 0.01; n = 6 of two preparations, Fig. 4B). Hence, the {alpha}5 genotypes were most distinct at 1 DIV, when potency ratios between DMPP and cytisine differed by the quotient 1.39/0.30 (i.e. 4.63). Overall, these data are consistent with changes in the nAChR composition with in vitro development of {alpha}5 (+/+) neurones that does not occur when the {alpha}5 subunit is absent.

TTX-sensitive versus TTX-insensitive transmitter release

Experiments delineated above assess the pharmacological fingerprints of somatic nAChRs in SCG neurones from both {alpha}5 (+/+) and {alpha}5 (–/–) mice. Our next task was to apply a similar analysis to determine the functional profile of the presynaptic receptor pools. As detailed in a previous study (Kristufek et al. 1999), the function of prejunctional receptors was monitored indirectly by measuring the outflow of preloaded [3H]NA in response to nicotinic agonists. The component of transmitter outflow that remains upon stimulation with nicotine in the presence of TTX (‘TTX-insensitive transmitter release’) thus reflects the function of presynaptic receptors (Kristufek et al. 1999). Subtraction of this component from overall release (i.e. in the absence of TTX) reveals the ‘TTX-sensitive component’.

We first examined whether SCG neurones from mice, like those from rat, have both the TTX-sensitive as well as the TTX-insensitive component. Results from these experiments for both {alpha}5 (+/+) and {alpha}5 (–/–) animals are shown in Fig. 5. Curve fits of data points by eqn (2) yielded identical EC50 values for the TTX-insensitive component of nicotine-induced transmitter outflow in {alpha}5 (+/+) and {alpha}5 (–/–) mice ({alpha}5 (+/+), 37.46 µM; {alpha}5 (–/–), 37.04 µM, Fig. 5). Note, however, that the maximum of the TTX-insensitive component was strikingly different between {alpha}5 (–/–) and {alpha}5 (+/+) mice. As shown in more detail below (Fig. 7), TTX-insensitive transmitter release was significantly enhanced in {alpha}5 (–/–) mice not only in response to nicotine, but also by the other agonists tested.



View larger version (20K):
[in this window]
[in a new window]
 
Figure 5.  TTX-sensitive and TTX-insensitive transmitter release in {alpha}5 (+/+) and {alpha}5 (–/–) mice
A1, exploring full concentration–response curves in {alpha}5 (+/+) mice. Nicotine-induced transmitter release from 5 DIV SCG cultures under control conditions (overall release, {blacktriangledown}) and in the presence of 0.25 µM TTX (TTX-insensitive release, {blacksquare}). Data are means ± S.E.M., n = 3 individual culture discs. Data points indicated by circles (TTX-sensitive release) were obtained by subtracting mean values of nicotine-induced release in the presence of TTX ({blacksquare}) from overall release ({blacktriangledown}). A2, curve fits of TTX-sensitive ({circ}) and TTX-insensitive ({blacksquare}) nicotine-induced transmitter release by applying eqn (2) yielded the following parameters: EC50 TTX-sensitive, 15.82 ± 2.52 µM; EC50 TTX-insensitive, 37.46 ± 0.98 µM; maximal effect TTX-sensitive, 2.81 ± 0.22%; maximal effect TTX-insensitive, 3.47 ± 0.06%; slope factor p for TTX-sensitive, 2.03 ± 0.48; slope factor p for TTX-insensitive, 4.82 ± 0.42. Data points for the curve fits were taken from A1. A3, exploring the low concentration end of the dose–response curve. Nicotine-induced transmitter release from 2 DIV SCG cultures of {alpha}5 (+/+) mice under control conditions (overall release, {blacktriangledown}) and in the presence of 0.25 µM TTX (TTX-insensitive release, {blacksquare}). Means ± S.E.M., n = 3 release experiments. Each data point was calculated from three triplets of individual culture discs. The data points indicated by circles (TTX-sensitive release) were obtained by subtracting mean values of nicotine-induced release in the presence of TTX ({blacksquare}) from overall release ({blacktriangledown}). Note that TTX-sensitive release reached a near maximal value of 5.52 ± 0.31% (n = 3 cultures in triplicate) at 30 µM nicotine. B1 and B2, same experimental protocols as shown in A1 and A2, except that transmitter release was determined in 4 DIV cultures obtained from {alpha}5 (–/–) mice. Fitting curves by eqn (2) to the data points shown in B1 yielded the following parameters: EC50 TTX-sensitive, 11.71 ± 2.13 µM; EC50 TTX-insensitive, 37.04 ± 0.56 µM; maximal effect TTX-sensitive, 5.23 ± 0.63%; maximal effect TTX-insensitive, 15.58 ± 0.18%; slope factor p for TTX-sensitive, 2.59 ± 1.01; slope factor p for TTX-insensitive, 3.58 ± 0.15. Note that in comparison with {alpha}5 (+/+) mice, the two preparations differ grossly in their maximal values of the TTX-insensitive component. B3, same experimental protocols as shown in A3, except that transmitter release was determined in 2 DIV cultures obtained from {alpha}5 (–/–) mice. Note that TTX-sensitive release reached a maximum of 5.79 ± 0.19% (n = 3 cultures in triplicate) in response to only 10 µM nicotine (versus 30 µM in {alpha}5 (+/+) mice).

 
TTX-sensitive release was induced with an EC50 of 15.82 µM in {alpha}5 (+/+) and an EC50 of 11.71 µM in {alpha}5 (–/–) mice (Fig. 5A2 and B2) and thus appeared to be more potently activated in animals lacking the {alpha}5 subunit. A plausible explanation for the higher potency of nicotine in inducing TTX-sensitive release in {alpha}5 (–/–) mice might be a higher efficacy of the agonists on nAChRs assembled without the contribution of {alpha}5 subunits. If this were the case, and assuming that neither the properties or distribution of voltage-gated sodium channels are affected by the {alpha}5 subunit genotype, a lower concentration of nicotine might suffice to depolarize neurones to the threshold level for the activation of sodium channels. We tested this hypothesis by exploring transmitter release upon exposure of cultures to low concentrations of nicotine in the presence and absence of TTX (Fig. 5A3 and B3). Our experiments revealed that the TTX-sensitive component reached about the same maximum in both {alpha}5 (+/+) and {alpha}5 (–/–) mice. However, maximal effects were obtained with 10 µM nicotine in {alpha}5 (–/–) animals, whereas it took about 30 µM of nicotine in {alpha}5 (+/+) mice (Fig. 5A3 and B3).

These observations are compatible with the idea that nAChRs assembled in {alpha}5 (–/–) mice are activated more efficaciously by nicotine than those in {alpha}5 (+/+) controls. Note that release measured in all cases is entirely dependent on the presence of calcium in the superfusion buffer even in {alpha}5 (–/–) animals, where the TTX-insensitive component of nicotine-induced transmitter release is markedly enhanced relative to control (Fig. 6). On average, 100 µM nicotine causes a 22.8 ± 4.1% (n = 24) depletion of radioactivity in cultures after 2 DIV (see Fig. 9).



View larger version (19K):
[in this window]
[in a new window]
 
Figure 6.  Calcium-dependence of TTX-insensitive transmitter release in {alpha}5 (–/–) mice
Basal transmitter release and the release induced by 100 µM nicotine (15 s, indicated by arrows) in the presence of 0.25 µM TTX. Control buffer containing 2 mM Ca2+ (cultures 3 DIV, {circ}); superfusion buffer with and without (indicated by horizontal bar) 2 mM Ca2+ (cultures 2 DIV, •). Data points are means ± S.E.M., n = 3.

 


View larger version (15K):
[in this window]
[in a new window]
 
Figure 9.  Time-dependence of the efficacy of nicotine at somatic and prejunctional receptors
A, somatic receptors: SCG cultures from either {alpha}5 (+/+) or {alpha}5 (–/–) mice were maintained for 1 DIV (open columns), 4/5 DIV (filled columns), or 7 DIV (hatched columns). Maximal effects of nicotine were determined by fitting eqn (2) to calcium transients in response to a full range of nicotine concentrations as shown in Fig. 1F. Note that nicotine exerted highest effects at 4/5 DIV both in {alpha}5 (+/+) and {alpha}5 (–/–) mice. In {alpha}5 (+/+) mice, values at 4/5 DIV were significantly larger than at 1 DIV (P < 0.05) or 7 DIV (P < 0.01). In {alpha}5 (–/–) mice, values at 4/5 DIV significantly exceed those at 7 DIV (P < 0.05). Maximal effects of nicotine were significantly larger in {alpha}5 (–/–) than in {alpha}5 (+/+) mice at 1 DIV and 7 DIV (P < 0.01). Data are means ± S.E.M., n = 9–27 individual cells. B, prejunctional receptors: transmitter release in response to 100 µM nicotine in the presence of 0.25 µM TTX. SCG cultures from either {alpha}5 (+/+) or {alpha}5 (–/–) mice were maintained for 2 DIV (open columns), 5 DIV (filled columns), or 8 DIV (hatched columns). Data are means ± S.E.M., n = 24 individual cultures (at 2 DIV), 12 (at 5 DIV) and 9 (at 8 DIV). Note that in the presence of TTX, 100 µM nicotine will cause maximal transmitter release (see Figs 5 and 7), and that at all ages, cultures obtained from {alpha}5 (–/–) mice showed significantly more agonist-induced NA release than {alpha}5 (+/+) animals. NA release in response to nicotine significantly declined between 5 DIV and 8 DIV both in {alpha}5 (+/+) and {alpha}5 (–/–) animals (P < 0.01), and between 2 DIV and 5 DIV in cultures taken from {alpha}5 (–/–) mice (P < 0.01).

 
Prejunctional nAChRs: assessment of function by full concentration–response curves of nicotinic agonists in {alpha}5 (+/+) and {alpha}5 (–/–) mice

Having assessed the basic properties of TTX-sensitive and TTX-insensitive transmitter release in both {alpha}5 (+/+) and {alpha}5 (–/–) mice we next examined the pharmacological profile of the prejunctional nAChRs in the {alpha}5 (+/+) and {alpha}5 (–/–) animals in more detail. EC50 values deduced from full concentration–response curves indicate a lower potency of DMPP and ACh, but not of nicotine or cytisine, in {alpha}5 (+/+) mice (Fig. 7; Table 2) as compared to the rat SCG (Kristufek et al. 1999). Potency ratios calculated from EC50 values relative to cytisine (1.0) in {alpha}5 (+/+) mice were: DMPP, 1.61; nicotine, 1.64; Ach, 0.28. In Sprague-Dawley rats, ratios were: DMPP, 2.17; nicotine, 1.41; and Ach, 0.43 (data in rats taken from Kristufek et al. 1999).

Deletion of the {alpha}5 subunit as evaluated from the transmitter release assay shifted the EC50 values of all agonists except of cytisine towards a higher potency (Fig. 7; Table 2). Nevertheless, potency ratios in {alpha}5 (+/+) controls closely resembled the values of {alpha}5 (–/–) animals (cytisine, 1; DMPP, 1.84; nicotine, 1.59; Ach, 0.47).

However, the most conspicuous effect of the deletion of the {alpha}5 subunit was the impact it had on the efficacy of nicotinic agonists: all agonists tested stimulated a higher level of release at significantly lower doses in {alpha}5 (–/–) compared with {alpha}5 (+/+) animals (Fig. 7F). Transmitter release upon activation of prejunctional receptors was enhanced by nearly 3-fold (Fig. 7F).

Prejunctional nAChRs: assessment of function by low-concentration potency ratios confirms results from full concentration–response curves

Analogous to our assessment of the function of somatic nAChRs mentioned above we sought confirmation of the potency ratios calculated from EC50 values by applying the two most discriminating agonists, cytisine and DMPP, at low concentrations (Fig. 8). After 5 DIV, DMPP was 2.12 ± 0.16 (n = 3 release experiments) and 2.00 ± 0.11 (n = 3 release experiments) times more potent than cytisine in the {alpha}5 (+/+) and {alpha}5 (–/–) animals, respectively (Fig. 8). In cultures examined between 2 DIV and 8 DIV, DMPP was consistently more potent than cytisine in both {alpha}5 (+/+) and {alpha}5 (–/–) animals (Fig. 8B1 and B2).

Age-dependent properties of SCG cultures: impact of the time in vitro on agonist efficacies

As mentioned above, the age of cultures had a significant impact on the relative potency of nicotinic agonists at somatic receptors in {alpha}5 (+/+) mice (Fig. 4). However, the age of cultures also affected the overall efficacy of nicotine. Hence, in both {alpha}5 (+/+) and {alpha}5 (–/–) animals, the increase of intracellular calcium obtained by nicotine reached a maximum at 4 DIV and declined markedly after 7 DIV (Fig. 9A).

The time course of the changes in efficacy of nicotine at prejunctional receptors was determined by measuring transmitter outflow in response to a standard concentration of 100 µM nicotine (in the presence of TTX) at several different DIV and for both the {alpha}5 (+/+) and {alpha}5 (–/–) genotypes (2, 5, and 8 DIV; Fig. 9B). As noted for somatic receptors, the efficacy of nicotine significantly declined between 5 and 8 DIV in both genotypes, and between 2 and 5 DIV in {alpha}5 (–/–) mice. The waning of the effect of nicotine between 5 and 8 DIV was not due to a general loss in the release capacity of cultures, as transmitter outflow in response to electrical field stimulation did not differ significantly either in {alpha}5 (+/+) or in {alpha}5 (–/–) mice between 5 and 8 DIV (P > 0.05; data not shown).

Prejunctional nAChRs: assessment of the efficacy of nicotine in the atrium preparation of {alpha}5 (+/+) and {alpha}5 (–/–) mice

We corroborated the increased efficacy of prejunctional nicotinic receptors in an acute atrium preparation taken from 6-day-old animals (Fig. 10). Transmitter release induced by a concentration of nicotine that we know caused maximal effect under conditions of action potential blockade (Figs 5 and 7) was significantly larger in {alpha}5 (–/–) compared to {alpha}5 (+/+) mice (Fig. 10). In contrast, transmitter release in response to electrical field stimulation was not affected by the genotype (Fig. 10).



View larger version (15K):
[in this window]
[in a new window]
 
Figure 10.  Transmitter release from acute mouse atrium preparations: comparison between {alpha}5 (+/+) and {alpha}5 (–/–) animals
Transmitter release overflow was evaluated in acute atrium preparations from 6-day-old animals upon preloading with [3H]NA as described in Methods. The figure shows basal overflow, overflow induced by electrical field stimulation (120 pulses, 3 Hz), and the overflow in response to 100 µM nicotine in the presence of 0.5 µM TTX. Data points are the mean overflow ± S.E.M. from nine (wild-type) or 12 (knockout) atria. Transmitter overflow induced by nicotine was significantly larger in {alpha}5 (–/–) compared to {alpha}5 (+/+) animals (P < 0.01). Basal and electrically induced overflow did not differ significantly between preparations obtained from either knockout or wild-type animals (P > 0.05).

 

    Discussion
 Top
 Abstract
 Introduction
 Methods
 Results
 Discussion
 References
 
Prior studies demonstrate distinct pharmacological properties of somatic–dendritic versus axonally targeted nAChRs of rat SCG neurones in vitro (Kristufek et al. 1999). The current study extends these observations by initiating a systematic analysis of the potential role of nAChR subunit composition in distinct receptor pools, using mice with targeted deletions of individual nAChR subunits (for reviews see Wang et al. 2002b; Champtiaux & Changeux, 2004; Dajas-Bailador & Wonnacott, 2004). In particular, this study explores the role of {alpha}5 subunits, testing whether pharmacological differences between somato-dendritic versus presynaptic nAChRs may be due, at least in part, to the distinct role of the {alpha}5 subunit in nAChRs in different neuronal domains.

The simplest summary of these combined genetic and pharmacological analyses is that {alpha}5 nAChR subunits differentially contribute to nAChR pools in different cellular locales. The most intriguing and unexpected finding from our results is the enhancement of presynaptic nAChR-mediated NA release consequent to the deletion of {alpha}5 subunits from axonally targeted nAChRs. The implications of these findings are discussed below.

Overall, we provide three new observations regarding the profile of nAChRs expressed by mouse SCG neurones in general and the contributions of the {alpha}5 nAChR subunit in particular: (1) the pharmacological profile of somatic nAChRs depends on developmental age and on the presence or absence of {alpha}5 subunit gene expression; (2) the pharmacological profile of presynaptic nAChRs differs from that of the somatic nAChRs by being independent of developmental age and of {alpha}5 subunit gene expression; and (3) the effects of {alpha}5 deletion are most evident in changes of presynaptic nAChRs, implicating {alpha}5 subunits in constraining the number and/or efficacy of nAChRs linked to the presynaptic facilitation of NA release. Complementary studies in more intact (acute atrium) preparations confirm the hypothesized role of {alpha}5 subunits in shaping nicotine-evoked NA release (Fig. 10).

Contribution of {alpha}5 subunits to somatic nAChRs

Our studies revealed both age- and {alpha}5 expression-dependent differences in somatic nAChRs, including significantly higher potency of cytisine compared to DMPP at early stages (1 DIV after removal of ganglia from P4/5 mice), whereas DMPP and cytisine were essentially equipotent after 1 week in vitro. In contrast, in mice lacking the {alpha}5-nAChR subunit, somatic nAChRs were described by a rank order potency of DMPP > cytisine irrespective of the age of cultures. These and other data (discussed below, and see McNerney et al. 2000; Skok, 2002; Vincler & Eisenach, 2003; Nai et al. 2003) are consistent with our suggestion that mature somatic nAChRs in mouse SCG include {alpha}3{alpha}5ß4* nAChRs as well as {alpha}3{alpha}5ß4ß2* nAChRs.

The rat SCG contains mRNA for {alpha}3, {alpha}5, {alpha}7, ß2 and ß4 (Mandelzys et al. 1995; De Koninck & Cooper, 1995; Zhou et al. 1998; D. Kristufek and S. Huck, unpublished observation). If we assume an identical subunit profile in the mouse, and if we further assume that the deletion of one subunit is not compensated by the appearance or up-regulation of another (see Kedmi et al. 2004), we should be able to assess the contribution of {alpha}5 to somatic nAChRs based on the differences in pharmacological profile per se. Elegant studies, using nAChR subunit-specific antibodies, have provided both immunohistochemical and immunoprecipitation-based evidence for the probable composition of peripheral neurone-type nAChRs in chick and human (Conroy & Berg, 1995; Wang et al. 1996; Gerzanich et al. 1998). Although comparable studies have yet to be done in rat or mouse, the prior work on other species, together with data from heterologous expression of known subunit combinations, provide important guidelines for the current study.

In the chick ciliary ganglion, most of the {alpha}5 gene product in fully assembled receptors is associated with both {alpha}3 and ß4 subunits. About 20% of these receptors also contain ß2 (Conroy & Berg, 1995). The first studies of {alpha}5 in heterologous recombination with other {alpha} and ß subunits examined {alpha}5 plus {alpha}4 and ß2 subunits from chick (Ramirez-Latorre et al. 1996). The {alpha}5{alpha}4ß2* nAChRs had a higher conductance and a faster rate of agonist-induced desensitization than nAChRs formed without {alpha}5. Co-transfection of chick {alpha}5 with {alpha}3ß4 in (human) BOSC 23 cells added an additional, low affinity component (EC50, 512 µM) of ACh-induced currents to the higher-affinity profile (EC50, 66 µM) seen with simple pairwise expression of {alpha}3 and ß4 (Fucile et al. 1997). These data, and our observations, are in keeping with findings in the chick SCG that functional deletion of the {alpha}5 subunit by antisense oligonucleotide treatment removes nAChRs with relatively low affinity to ACh and cytisine (Yu & Role, 1998b). However, cotransfection of chick {alpha}5 with {alpha}3ß4 in Xenopus oocytes, or of chick {alpha}5 with {alpha}3ß2 in BOSC 23 cells, had little effect on either the potency or the efficacy of ACh (Fucile et al. 1997).

In the human neuroblastoma SH-SY5Y cell line, both